Neuronetics Receives FDA 510(k) Clearance For NeuroSite Coil Placement Accessory That Simplifies Measurement And Coil Positioning During Neurostar Transcranial Magnetic Stimulation Treatments
Portfolio Pulse from Benzinga Newsdesk
Neuronetics, Inc. (NASDAQ:STIM) has received FDA 510(k) clearance for its NeuroSite Coil Placement Accessory, designed to simplify measurement and coil positioning during NeuroStar transcranial magnetic stimulation treatments. The accessory integrates with both legacy and new NeuroStar systems, aiming to enhance efficiency and patient experience. It uses patient's anatomical features for precise coil placement, reducing setup steps and is expected to be available to all NeuroStar providers in Q1 of 2024.
December 18, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
FDA clearance for Neuronetics' NeuroSite Coil Placement Accessory may boost investor confidence in STIM, reflecting the company's commitment to advancing medical technology in mental health.
FDA clearances are significant milestones for medical technology companies. This clearance demonstrates Neuronetics' ability to innovate and could lead to increased adoption of their NeuroStar TMS treatments, potentially boosting revenue. The news is likely to be viewed positively by investors, as it indicates progress in the company's product pipeline and commitment to improving mental health treatments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100